FDA APPROVED DRUGS:
RADICAVA AND RILUZOLE
What is Radicava?
Radicava (AKA Edaravone) is a free radical scavenger which has been shown to decrease progression in ALS patients. It was approved in May of 2017 and it was the first FDA approved ALS treatment drug in the past 23 years since Riluzole. Radicava, also called Radicut, is used intravenously after a stroke to treat ALS, helping patients recover after a stroke.
What is Riluzole?
Riluzole (AKA Rilutek) is a glutamate blocker which aids in expelling glutamate excitotoxicity in the body. FDA approved in 1995, the drug may increase survival by approximately two to three months.
What is Relyvrio?
RELYVRIO (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS. Relyvrio can help slow the progression of ALS, preserve physical function and potentially extend survival has the potential to greatly impact the hundreds of people living with ALS.